LILRA4 靶点蛋白|抗体药物|临床药物信息

LILRA4信息

英文名称：Leukocyte immunoglobulin-like receptor subfamily A member 4
中文名称：人白细胞免疫球蛋白样受体亚家族A成员4
靶点别称：ILT7，CD85g，Immunoglobulin-like transcript 7，LILRA4，Leukocyte Immunoglobulin Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (With TM Domain)， Member 4，CD85 Antigen-Like Family Member G，Leucocyte Ig-Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (Without TM Domain)， Member 4，Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 4，CD85g Antigen，ILT-7

上市药物数量：0
临床药物数量：1
最高研发阶段：临床二期

LILRA4产品列表

筛选结果

产品库

在线 (1)

物种

Human (1)

标签

His Tag (1)

属性

Protein (1)

标记

Unconjugated (1)

货号	物种	产品描述	蛋白结构	纯度	活性
LI4-H5243	Human	Human LILRA4 / CD85g / ILT7 Protein, His Tag (MALS verified)

LILRA4 分子别名

LILRA4,CD85g,ILT7,ILT-7

LILRA4 分子背景

Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4/ILT7/CD85g) is a marker of plasmacytoid dendritic cells (pDCs), which are reported to be a major source of the abnormally high levels of IFNα associated with autoimmune diseases. Targeting LILRA4 with therapeutic antibodies to promote killing of these IFNα-producing pDCs is being investigated as a novel approach to alleviating the symptoms of autoimmune diseases. LILRA4 is an immunoglobulin-like protein preferentially expressed on the surface of human plasmacytoid dendritic cells (pDCs). It interacts with bone marrow stromal cell antigen 2 to control the Toll-like receptor (TLR) driven response by pDCs to viral infection. It may also be involved in modulating pDC-tumour interactions. pDCs are a source of the excess IFNα which drives autoimmune disease symptoms.

LILRA4 前沿进展

LILRA4临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
Daxdilimab	MEDI-7734; VIB-7734; HZN-7734	临床二期	Sbi Biotech Co Ltd, Horizon Therapeutics PLC	多发性肌炎, 皮肌炎, 斑秃, 盘状红斑狼疮, 肌炎, Sjtoegren综合征, 皮肤红斑狼疮, 系统性硬皮病, 狼疮肾炎, 系统性红斑狼疮, 急性肺损伤	详情

会议日历

会议一览

LILRA4